SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193805-24-000234
Filing Date
2024-02-15
Accepted
2024-02-15 17:20:24
Documents
2
Group Members
DEERFIELD HEALTHCARE INNOVATIONS FUND, L.P.DEERFIELD MANAGEMENT COMPANY, L.P.DEERFIELD MGMT HIF, L.P.DEERFIELD MGMT III, L.P.DEERFIELD MGMT, IV, L.P.DEERFIELD MGMT, L.P.DEERFIELD PARTNERS, L.P.DEERFIELD PRIVATE DESIGN FUND III, L.P.DEERFIELD PRIVATE DESIG

Document Format Files

Seq Description Document Type Size
1 e619280_sc13da-lt.htm SC 13D/A 212634
2 e619280_ex99-i.htm EX-99.I 27693
  Complete submission text file 0001193805-24-000234.txt   242262
Mailing Address 780 THIRD AVENUE 37TH FLOOR NEW YORK NY 10017
Business Address
Flynn James E (Filed by) CIK: 0001352546 (see all company filings)

Type: SC 13D/A

Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Subject) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88225 | Film No.: 24644881
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)